Morning Overview on MSN
An experimental drug cut the risk of death from a common lung cancer by 34% in a trial
Patients with advanced squamous non-small cell lung cancer who received the experimental bispecific antibody ivonescimab ...
Survival in the transplant group was also similar to a cohort of non-cancer patients who underwent lung transplantation for ...
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in ...
Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...
Non–small cell lung cancer (NSCLC), a malignancy that forms in the tissues of the lungs, accounts for the majority of lung ...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in ...
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results